Fire1 Raises $120M for Heart Failure Management System Trial

Fire1 announced a $120 million funding round to complete pivotal trials of its Norm heart failure management system, a device that monitors fluid volume in the inferior vena cava to provide real-time insights into heart function. Unlike existing devices such as Abbott’s Cardiomems, which track pulmonary artery pressure, Norm offers a unique approach by measuring fluid volume to manage heart failure. The system consists of an implantable sensor, a wearable belt for data transmission, and apps that deliver actionable insights to patients and clinicians. With breakthrough device designation from the FDA, Fire1 is advancing toward regulatory approval and commercialization.

The funding round, led by Polaris Partners and Elevage Medical Technologies, saw participation from new investors Sands Capital and Longitude Capital, as well as existing backers including Medtronic and Novo Holdings. Emerging from the California-based medical device incubator The Foundry, Fire1 joins a lineage of successful startups acquired by major medtech players. With these resources, Fire1 aims to establish Norm as a competitive alternative to devices like Abbott’s Cardiomems and Edwards Lifesciences’ Cordella, furthering innovation in heart failure management.